Key clinical point: When compared with conventional immunosuppression, posttransplant cyclophosphamide can reduce graft-versus-host disease without affecting relapse.

Major finding: The graft-versus-host disease–free and relapse-free survival at 12 months was 22% in the conventional immunosuppression arm and 45% in the posttransplant cyclophosphamide arm (P = .001).

Study details: A phase 3 trial of 160 patients with hematologic malignancies undergoing allogeneic transplant.

Disclosures: The study was funded by the Dutch Cancer Society, and Novartis provided the mycophenolic acid used in the study. Dr. Broers reported having no conflicts of interest.